One such compound is deltarasin, which interacts with PDE6δ with high affinity and prevents recognizing the posttranslational modification present on KRas4B, causing accumulation of KRas4B in the cytosol, thus preventing KRas4B activation and tumor progression (Zimmermann et al, 2013). Here, KRAS is linked to neoplasm.